Drug slows Alzheimer's but can it make a real difference? nejm
The accumulation of soluble and insoluble aggregated amyloid-beta may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer’s disease.
A total of 1795 participants were enrolled, with 898 assigned to receive lecanemab and 897 to receive placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo . In a substudy involving 698 participants, there were greater reductions in brain amyloid burden with lecanemab than with placebo .
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Biomarker in urine could be the first to reveal early-stage Alzheimer's diseaseAlzheimer's disease can remain undetected until it is too late to treat. Large-scale screening programs could help to detect early-stage disease, but current diagnostic methods are too cumbersome and expensive. Now, a new study is the first to identify formic acid as a sensitive urinary biomarker that can reveal early-stage Alzheimer's disease, potentially paving the way for inexpensive and convenient disease screening.
Læs mere »
Lecanemab: New Alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementia'It confirms a new era of disease modification for Alzheimer's disease, an era that comes after more than 20 years of hard work by many, many people, with many disappointments along the way.'
Læs mere »
AI predicts heart disease risk using single X-rayResearchers have developed a deep learning model that uses a single chest X-ray to predict the 10-year risk of death from a heart attack or stroke stemming from atherosclerotic cardiovascular disease. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).
Læs mere »
Small UK study investigates the effectiveness of a single MVA-BN dose against mpox diseaseResearchers estimated the single-dose MVA-BN vaccine effectiveness against symptomatic mpox among high-risk gay, bisexual and other men who have sex with men in England.
Læs mere »
New single-dose treatment for sleeping sickness could help eliminate transmission of the disease by 2030A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases.
Læs mere »
Gut microbial flavonoid catabolite reverses fatty liver disease in miceGut microbial flavonoid catabolite reverses fatty liver disease in mice FattyLiver Hepatic Steatosis Liver LiverDisease flavonoid catabolite PNASNews ClevelandClinic
Læs mere »